



IN THE CLAIMS:

Please cancel claim 13-15, 32, 36 and 37 without prejudice or disclaimer as directed to non-elected subject matter.

Please amend the claims as follows:

6. (Twice amended) The epithelial tumor cell according to claim 1, wherein said immortalizing oncogene is the DNA encoding the early region of SV40 DNA [and preferably the large T antigen of a replication deficient SV40 virus].

B3 7. (Twice amended) The epithelial tumor cell according to claim [6] 38, wherein [said] the replication deficiency of said replication deficient SV40 virus is caused by at least one defect in the origin of replication, at least one defect in the antigen coding region or a combination thereof.

B4 33. (Once amended) A [pharmaceutical] composition comprising the epithelial tumor cell according to claim 1[, or an antibody molecule selected from the group consisting of an antibody, a fragment of said antibody, a derivative of said antibody or a fragment of said derivative, wherein said antibody molecule specifically recognizes said epithelial tumor cell], optionally in combination, with a pharmaceutically acceptable carrier.

34. (Once amended) The [pharmaceutical] composition according to claim 33, wherein said composition comprises a vaccine in combination with a vaccine adjuvant.

Kindly add the following claims:

B5 --38. The epithelial tumor cell according to claim 6, wherein said early region of SV40 DNA is the large T antigen of a replication deficient SV40 virus.--

ADD
E3

REMARKS

Claims 1-22 and 29-37 are pending in this application. Claims 13-15, 32, 36 and 37 are canceled and language in claim 33 is deleted without prejudice or disclaimer as drawn to non-elected subject matter. Applicants reserve the right to file the subject matter of these claims in a divisional application. Claims 6, 7, 33 and 34 are amended and claim 38 is added. Applicants confirm the election of Group I, claims 1-12, 16-22, 29-31, 32 and 34